Summary
Biogen Inc. (BIIB) filed an 8-K on November 19, 2021, to report a significant update regarding Tecfidera (dimethyl fumarate). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued an opinion stating that based on available data, it cannot be concluded that monoethyl fumarate salts (MEF) within Fumaderm demonstrate a clinically relevant therapeutic effect. This opinion is in the context of an ongoing legal dispute stemming from a General Court judgment that annulled the EMA's non-validation decision for a generic Tecfidera application. Biogen, the EMA, and the European Commission have appealed this General Court decision.
Key Highlights
- 1CHMP of EMA issued an opinion on the therapeutic effect of MEF in Fumaderm.
- 2The CHMP concluded that a clinically relevant therapeutic effect of MEF in Fumaderm has not been demonstrated based on the available data.
- 3The opinion cites severe methodological limitations in the clinical studies considered.
- 4This development is related to an ongoing appeal concerning a General Court's judgment that annulled an EMA decision on a generic Tecfidera application.
- 5Biogen, the EMA, and the European Commission have appealed the General Court's decision.
- 6The filing does not provide new financial statements or exhibits beyond the cover page interactive data file.
Frequently Asked Questions
The CHMP's opinion that MEF in Fumaderm has not demonstrated a clinically relevant therapeutic effect could impact the regulatory landscape for Tecfidera and its generics in Europe, particularly in the context of the ongoing legal challenge to a generic application. While Tecfidera itself is not directly addressed in the opinion, the underlying issue pertains to the efficacy of fumarate derivatives.
The legal dispute arises from a General Court (Case T-611/18) judgment that annulled the EMA's previous decision to not validate a generic application for Tecfidera. Biogen, the EMA, and the European Commission are appealing this judgment, viewing it as wrongly decided.
This specific CHMP opinion relates to an ad hoc assessment for Fumaderm and the context of a generic application challenge. It does not appear to directly revoke or suspend current marketing authorizations for Tecfidera in the EU. However, the ongoing legal appeals and the CHMP's views on therapeutic effect could have future implications for the market and regulatory environment.
Monoethyl fumarate salts (MEF) are metabolites of dimethyl fumarate, the active ingredient in Tecfidera. Fumaderm is a different product containing fumaric acid esters, which has been used in Germany for treating psoriasis. The CHMP's opinion was on the therapeutic effect of MEF within Fumaderm, referencing clinical studies.